Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Novo Holdings

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 350
Average round size
info
The average size of a deal this fund participated in
$55M
Portfolio companies 220
Rounds per year 14.00
Lead investments 38
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.37
Exits 74
Key employees Soon
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity
Seed

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Medical
  • Therapeutics

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Novo Holdings:
Typical Co-investors
Novo Holdings is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Novo Holdings:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Myricx Pharma

Biotechnology
Life Science
$123M08 Jul 2024 United Kingdom, England, United Kingdom

MATR Foods

Food and Beverage
Food Processing
Organic Food
01 Jul 2024 Copenhagen, Hovedstaden, Denmark

ADCendo

Biotechnology
$18M29 May 2024 Copenhagen, Capital Region of Denmark, Denmark

Commit Biologics

Biotechnology
Life Science
Medical
Therapeutics
$18M09 May 2024 Aarhus, Midtjylland, Denmark

Reunion Neuroscience

Biotechnology
Pharmaceutical
$103M02 May 2024 Toronto, Ontario, Canada

Reduced

$7M04 Apr 2024 Copenhagen, Hovedstaden, Denmark

Obsidian Therapeutics

Biotechnology
Health Care
Pharmaceutical
$160M03 Apr 2024 Cambridge, Massachusetts, United States

Clasp Therapeutics

$150M20 Mar 2024 Cambridge, Massachusetts, United States

Asgard Therapeutics

Biotechnology
Therapeutics
$35M14 Mar 2024 Lund, Skane Lan, Sweden

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Novo Holdings?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 350
Average round size 55M
Rounds per year 14.00
Peak activity year 2020
Lead investments 38
Follow on index 0.37
Exits 74
Group Appearance index 0.88

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Myricx Pharma

Biotechnology
Life Science
$123M08 Jul 2024 United Kingdom, England, United Kingdom

MATR Foods

Food and Beverage
Food Processing
Organic Food
01 Jul 2024 Copenhagen, Hovedstaden, Denmark

ADCendo

Biotechnology
$18M29 May 2024 Copenhagen, Capital Region of Denmark, Denmark

Commit Biologics

Biotechnology
Life Science
Medical
Therapeutics
$18M09 May 2024 Aarhus, Midtjylland, Denmark

Reunion Neuroscience

Biotechnology
Pharmaceutical
$103M02 May 2024 Toronto, Ontario, Canada

Reduced

$7M04 Apr 2024 Copenhagen, Hovedstaden, Denmark

Obsidian Therapeutics

Biotechnology
Health Care
Pharmaceutical
$160M03 Apr 2024 Cambridge, Massachusetts, United States

Clasp Therapeutics

$150M20 Mar 2024 Cambridge, Massachusetts, United States

Asgard Therapeutics

Biotechnology
Therapeutics
$35M14 Mar 2024 Lund, Skane Lan, Sweden
Crunchbase icon

Content report

The following text will be sent to our editors: